Why the study?
Does liposomal doxorubicin-based chemotherapy improve ORR and reduce cardiotoxicity in patients with advanced breast cancer?
Does liposomal doxorubicin-based chemotherapy improve ORR and reduce cardiotoxicity in patients with advanced breast cancer?
Liposomal doxorubicin-based chemotherapy improves objective response rates and reduces cardiotoxicity in advanced breast cancer.
May support liposomal doxorubicin preference in advanced breast cancer for better response and cardiac safety; extends pooled evidence.
The results of this meta-analysis suggest that liposomal doxorubicin-based chemotherapy is associated with a significant improvement in the ORR and a significant reduction in the risk of cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Xing et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: